This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Guilford Pharmaceuticals Inc.
Guilford Pharmaceuticals Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in the late 1990s, the company has established itself as a leader in developing innovative therapies for central nervous system disorders and oncology. With a focus on delivering unique drug formulations, Guilford Pharmaceuticals has made significant strides in improving patient outcomes through its advanced product pipeline. The company’s core offerings include specialised treatments that leverage cutting-edge technology, setting them apart in a competitive market. Notable achievements include successful collaborations and regulatory approvals that have bolstered its market position. As Guilford Pharmaceuticals continues to expand its operational reach, it remains committed to advancing healthcare solutions that address unmet medical needs.
DitchCarbon Score
How does Guilford Pharmaceuticals Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Guilford Pharmaceuticals Inc.'s score of 57 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Guilford Pharmaceuticals Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company is part of a corporate family that includes Eisai Co., Ltd., from which it inherits climate commitments and initiatives. As a merged entity, Guilford Pharmaceuticals Inc. aligns its climate strategies with those of Eisai Co., Ltd., which has established various sustainability initiatives. However, specific reduction targets or achievements for Guilford Pharmaceuticals Inc. are not detailed in the available data. The absence of direct emissions data suggests that Guilford Pharmaceuticals may be in the early stages of formalising its climate commitments or reporting practices. The company is expected to follow the broader sustainability framework set by Eisai Co., Ltd., which includes participation in initiatives such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). Overall, while Guilford Pharmaceuticals Inc. does not currently provide specific emissions data or reduction targets, its affiliation with Eisai Co., Ltd. indicates a commitment to addressing climate change through inherited corporate sustainability practices.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 49,457,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 55,830,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 456,386,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Guilford Pharmaceuticals Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
